Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    29-August-2000      
Issue 138 Next Update - 14:00 UTC 08:00 EST    30-August-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya Additional Prescription Dispensing Errors Involving Lamictal Tablets And Lamisil Tablets Reported

Errors Can Result In Serious Adverse Events

Medication dispensing errors are a serious threat to quality health care and necessitate the combined efforts of prescribers, dispensers, manufacturers and patients to minimize their occurrence. Glaxo Wellcome Inc. has received reports of dispensing errors involving Lamictal ® (lamotrigine) Tablets and other prescription drugs; most of these errors have been with the prescription medication Lamisil ® (terbinafine hydrochloride) Tablets, some of which have resulted in serious adverse events.

The assistance of health professionals is requested in clearly communicating oral and written prescriptions for these two products to help avoid future dispensing errors. For example, professionals might consider, when appropriate, including the intended use on prescriptions for these products. Please alert patients for whom the medication is prescribed that they should carefully check the medication they receive and promptly bring any questions or concerns to the attention of the pharmacist. Additional efforts to address this situation within pharmacies are under way.

The error reports involve dispensing Lamisil Tablets when ®Tablets were prescribed and the reverse scenario. Patients erroneously receiving either medication would be unnecessarily subjected to the risk of adverse events. In addition, patients with epilepsy who do not receive their antiepileptic drug due to a dispensing error would be inadequately treated and could experience serious consequences including status epilepticus. Patients erroneously receiving Lamictal instead of their antifungal drug Lamisil would not have the dose of Lamictal properly titrated and would be unnecessarily subjected to a risk of potential side effects, including serious rash.

Lamictal is an antiepileptic drug marketed as 25-mg (white), 100-mg (peach), 150-mg (cream), and 200-mg (blue), shield-shaped tablets bearing "Lamictal " and the numeric representation of the strength (e.g., "Lamictal ®150"). Lamictal Chewable Dispersible Tablets are 5mg and 25mg white tablets engraved with "GX CL2" and "GX CL5," respectively.

Lamisil is an antifungal drug marketed as 250-mg circular tablets bearing "Lamisil" on one side and "250" on the other side.

Clear communication when prescribing any drug product is an important measure in the effort to reduce the occurrence of dispensing errors. If you become aware of a prescription dispensing error involving Lamictal ®, please contact Glaxo Wellcome Inc. at 1-800-334-4153; the USP Medication Errors Reporting Program (1-800- 233-7767) or the FDA MEDWATCH program by phone 1-800-FDA-1088, by FAX 1-800-FDA-0178, by Internet, or by mail:

5600 Fishers Lane
Rockville, MD 20857

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.